Cargando…

Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis

In patients with cystic fibrosis (CF), multidrug-resistant (MDR) bacteria can predispose to exacerbations, limit the effectiveness of antibiotic treatments and promote the progression of lung disease. The aim of this retrospective study was to compare pulmonary exacerbations (Pex), hospitalizations,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fainardi, Valentina, Neglia, Cosimo, Muscarà, Maria, Spaggiari, Cinzia, Tornesello, Marco, Grandinetti, Roberto, Argentiero, Alberto, Calderaro, Adriana, Esposito, Susanna, Pisi, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497623/
https://www.ncbi.nlm.nih.gov/pubmed/36138639
http://dx.doi.org/10.3390/children9091330
_version_ 1784794551641178112
author Fainardi, Valentina
Neglia, Cosimo
Muscarà, Maria
Spaggiari, Cinzia
Tornesello, Marco
Grandinetti, Roberto
Argentiero, Alberto
Calderaro, Adriana
Esposito, Susanna
Pisi, Giovanna
author_facet Fainardi, Valentina
Neglia, Cosimo
Muscarà, Maria
Spaggiari, Cinzia
Tornesello, Marco
Grandinetti, Roberto
Argentiero, Alberto
Calderaro, Adriana
Esposito, Susanna
Pisi, Giovanna
author_sort Fainardi, Valentina
collection PubMed
description In patients with cystic fibrosis (CF), multidrug-resistant (MDR) bacteria can predispose to exacerbations, limit the effectiveness of antibiotic treatments and promote the progression of lung disease. The aim of this retrospective study was to compare pulmonary exacerbations (Pex), hospitalizations, lung function and nutritional status in a group of children and adolescents with CF colonized by MDR bacteria and in a noncolonized control group. Overall, 7/54 pediatric patients (12.9%) were colonized by MDR bacteria and enrolled (3 with Achromobacter xyloxidans, 3 with Stenotrophomonas maltophilia and 1 with Burkholderia cepacia). The control group included 14 sex- and age-matched CF patients (8/14 colonized by Staphylococcus aureus, 2/14 by Pseudomonas aeruginosa, 2/14 by both microorganisms and 2/14 germ free). At the time of enrollment and 12 months before the first detection of the MDR microorganism, children colonized by MDR bacteria showed lower body mass index (BMI) and lower FEV(1)/FVC compared to the control group. Over the previous year before the first detection, children colonized with MDR had more Pex compared to control group; those colonized by S. maltophilia experienced the highest number of Pex. In the 12 months following the first detection of MDR bacteria, all seven patients colonized by MDR had at least one Pex and patients colonized by S. maltophilia had the highest number (mean ± SD: 6 ± 2.6 vs. 1.7 ± 2.3). Our study suggests that CF pediatric patients infected by MDR bacteria have lower BMI, more obstructive disease and experience more exacerbations than patients without MDR bacteria. These differences are present even before being infected, suggesting that children and adolescents with more severe disease are predisposed to be colonized by MDR bacteria. S. maltophilia appeared to be the most aggressive pathogen. Further studies and the implementation of antimicrobial stewardship programs are necessary to clarify when and how to treat patients with CF and MDR bacteria in order to avoid the improper use of antibiotics and the development of antibiotic resistance.
format Online
Article
Text
id pubmed-9497623
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94976232022-09-23 Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis Fainardi, Valentina Neglia, Cosimo Muscarà, Maria Spaggiari, Cinzia Tornesello, Marco Grandinetti, Roberto Argentiero, Alberto Calderaro, Adriana Esposito, Susanna Pisi, Giovanna Children (Basel) Article In patients with cystic fibrosis (CF), multidrug-resistant (MDR) bacteria can predispose to exacerbations, limit the effectiveness of antibiotic treatments and promote the progression of lung disease. The aim of this retrospective study was to compare pulmonary exacerbations (Pex), hospitalizations, lung function and nutritional status in a group of children and adolescents with CF colonized by MDR bacteria and in a noncolonized control group. Overall, 7/54 pediatric patients (12.9%) were colonized by MDR bacteria and enrolled (3 with Achromobacter xyloxidans, 3 with Stenotrophomonas maltophilia and 1 with Burkholderia cepacia). The control group included 14 sex- and age-matched CF patients (8/14 colonized by Staphylococcus aureus, 2/14 by Pseudomonas aeruginosa, 2/14 by both microorganisms and 2/14 germ free). At the time of enrollment and 12 months before the first detection of the MDR microorganism, children colonized by MDR bacteria showed lower body mass index (BMI) and lower FEV(1)/FVC compared to the control group. Over the previous year before the first detection, children colonized with MDR had more Pex compared to control group; those colonized by S. maltophilia experienced the highest number of Pex. In the 12 months following the first detection of MDR bacteria, all seven patients colonized by MDR had at least one Pex and patients colonized by S. maltophilia had the highest number (mean ± SD: 6 ± 2.6 vs. 1.7 ± 2.3). Our study suggests that CF pediatric patients infected by MDR bacteria have lower BMI, more obstructive disease and experience more exacerbations than patients without MDR bacteria. These differences are present even before being infected, suggesting that children and adolescents with more severe disease are predisposed to be colonized by MDR bacteria. S. maltophilia appeared to be the most aggressive pathogen. Further studies and the implementation of antimicrobial stewardship programs are necessary to clarify when and how to treat patients with CF and MDR bacteria in order to avoid the improper use of antibiotics and the development of antibiotic resistance. MDPI 2022-09-01 /pmc/articles/PMC9497623/ /pubmed/36138639 http://dx.doi.org/10.3390/children9091330 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fainardi, Valentina
Neglia, Cosimo
Muscarà, Maria
Spaggiari, Cinzia
Tornesello, Marco
Grandinetti, Roberto
Argentiero, Alberto
Calderaro, Adriana
Esposito, Susanna
Pisi, Giovanna
Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
title Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
title_full Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
title_fullStr Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
title_full_unstemmed Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
title_short Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
title_sort multidrug-resistant bacteria in children and adolescents with cystic fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497623/
https://www.ncbi.nlm.nih.gov/pubmed/36138639
http://dx.doi.org/10.3390/children9091330
work_keys_str_mv AT fainardivalentina multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT negliacosimo multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT muscaramaria multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT spaggiaricinzia multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT tornesellomarco multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT grandinettiroberto multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT argentieroalberto multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT calderaroadriana multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT espositosusanna multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis
AT pisigiovanna multidrugresistantbacteriainchildrenandadolescentswithcysticfibrosis